Total trials
130
Active
18
Phase 3
22
Total enrollment
20,583
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Zanubrutinib | — | 30 | |||||
| Tislelizumab | — | — | — | 60 | |||
| Cisplatin | — | — | — | 16 | |||
| Carboplatin | — | — | — | 12 | |||
| Paclitaxel | — | — | — | 13 | |||
| Pamiparib | — | — | — | 8 | |||
| Rituximab | — | — | — | — | 3 | ||
| Bendamustine | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Gemcitabine Hydrochloride | — | — | — | — | — | 1 | |
| Pemetrexed Disodium | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| BGB-11417 | — | — | — | — | 3 | ||
| LBL-007 | — | — | — | — | — | 3 | |
| BGB-A445 | — | — | — | — | 3 | ||
| Pemetrexed | — | — | — | 7 | |||
| Nab paclitaxel | — | — | — | — | 3 | ||
| BGB-15025 | — | — | — | — | 3 | ||
| Alcestobart | — | — | — | — | — | 3 | |
| BGB-16673 | — | — | — | — | 3 | ||
| BGB-A425 | — | — | — | — | — | 1 | |
| Bevacizumab or Bevacizumab biosimilar | — | — | — | — | — | 1 | |
| Fluoropyrimidine | — | — | — | — | — | 1 | |
| BGB-43395 | — | — | — | — | — | 2 | |
| BG-68501 | — | — | — | — | — | 1 | |
| Fulvestrant | — | — | — | — | — | 1 | |
| Tislelizumab IV | — | — | — | — | — | 1 | |
| Tislelizumab SC | — | — | — | — | — | 1 | |
| Histology-Based Chemotherapy Doublet | — | — | — | — | — | 1 |
Next readouts
- 2021-05-07
- 2023-08-21
- 2025-01-24
- 2025-05-23
- 2025-05-27
- 2025-06-17
- 2025-07-18
- 2025-07-31
- 2025-12-01
- 2025-12-31
Top conditions
- Healthy Volunteers11
- Advanced Solid Tumor7
- Advanced Solid Tumors6
- Marginal Zone Lymphoma5
- Solid Tumors4
- Small Lymphocytic Lymphoma4
- Non-small Cell Lung Cancer4
- Non Small Cell Lung Cancer4
Frequently asked questions about BeiGene
- How many clinical trials does BeiGene have on ClinicalTrials.gov?
- BeiGene is listed as the lead sponsor on 130 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of BeiGene's trials are in Phase 3?
- 22 of BeiGene's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does BeiGene focus on?
- BeiGene's most-studied conditions on ClinicalTrials.gov are Healthy Volunteers, Advanced Solid Tumor, Advanced Solid Tumors, Marginal Zone Lymphoma, Solid Tumors.
- When are BeiGene's next clinical trial readouts?
- BeiGene has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL”, expected around 2021-05-07.